20 miliardi di euro l’anno: i costi per il cancro in Italia – Prevenzione attiva, la vera arma vincente
We aim to shift the cancer prevention testing paradigm from early detection to cancer driver interception. On the global market, we want to introduce methodologies and services to identify the physiological conditions that drive solid tumor development in symptom-free individuals. To do so, we will leverage our AI-based monitoring program to screen for cancer driver conditions, and we will commit to our tool optimization for high levels of accuracy and sensitivity.
We will focus first on colorectal cancer to prove the methodology’s principle, fine-tune our approach, and raise awareness about the potentialities of the Cancer Driver Interception. We firmly believe that, shortly, HELIXAFE will become the scientific preventive tool for any solid cancer in support of the current general suggestions of a healthy lifestyle.
